These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29078211)

  • 1. [Personalized therapy of lung cancer - current standard and future challenges].
    Riedel R; Wolf J
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].
    Heigener DF; Horn M; Reck M
    Internist (Berl); 2016 Dec; 57(12):1243-1249. PubMed ID: 27587193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successes and limitations of targeted cancer therapy in lung cancer.
    Suda K; Mitsudomi T
    Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
    O'Neill AC; Jagannathan JP; Ramaiya NH
    Korean J Radiol; 2017; 18(1):6-17. PubMed ID: 28096714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
    Reckamp KL
    J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
    Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
    Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of targeted therapy in non-small cell lung cancer.
    Parums DV
    Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
    Halliday PR; Blakely CM; Bivona TG
    Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
    Gomes F; Tay R; Chiramel J; Califano R
    Drugs Aging; 2018 Sep; 35(9):819-834. PubMed ID: 30105645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapy for Non-Small Cell Lung Cancer.
    Noor ZS; Cummings AL; Johnson MM; Spiegel ML; Goldman JW
    Semin Respir Crit Care Med; 2020 Jun; 41(3):409-434. PubMed ID: 32450595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Evers G; Mohr M; Kerkhoff A; Lenz G; Wiewrodt R; Schmidt LH
    Dtsch Med Wochenschr; 2017 Oct; 142(20):1531-1534. PubMed ID: 29017211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
    Nokin MJ; Ambrogio C; Nadal E; Santamaria D
    Trends Cancer; 2021 May; 7(5):410-429. PubMed ID: 33309239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer.
    Kureshi N; Abidi SS; Blouin C
    IEEE J Biomed Health Inform; 2016 Jan; 20(1):424-31. PubMed ID: 25494516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targeted therapies in non-small cell lung cancer.
    Khanal N; Ganti AK
    Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.